Roche's obesity treatment candidate, enisefatide, has been shown in Phase 2 trials to significantly lower both blood sugar levels and weight in overweight and obese patients with type 2 diabetes.

Reuters Yonhap News

Reuters Yonhap News

View original image

On September 22 (local time), Roche announced that, after 48 weeks of treatment, the highest dose group (24 mg) saw a decrease in hemoglobin A1c (HbA1c) by 2.65 percentage points, while body weight was reduced by an average of 15.5%. The company also explained that the weight loss effect had not plateaued even at this time point.


Roche plans to begin a Phase 3 clinical trial and a cardiovascular outcome study in the first half of 2027. Enisefatide is a once-weekly GLP-1/GIP dual agonist. Its former code name was CT-388.



Levi Garraway, Chief Medical Officer (CMO) and Head of Global Product Development at Roche, stated, "Enisefatide has the potential to reduce and prevent complications in patients with type 2 diabetes, as well as improve metabolic health, based on its sustained weight loss effect." He added, "It demonstrates the potential to become a best-in-class therapy in the field of disease treatment."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing